{"classes":[{"categories":[{"measurements":[{"comment":"Here \"NA\" indicates that upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"28.68","upperLimit":"NA","value":"28.85"},{"groupId":"OG001","lowerLimit":"15.93","upperLimit":"25.10","value":"21.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"description":"DOR is defined as the interval between the date of initial documentation of a response including partial response with lymphocytosis (PRL) and the date of first documented evidence of PD or death or date of censoring per the IRC assessment. iWCLL 2008 criteria for PD: New enlarged nodes \\>1.5 cm, new hepatomegaly or splenomegaly, or other organ infiltrates; \\>= 50% increase from nadir in existing lymph node or \\>=50% increase from nadir in sum of product of diameters of multiple nodes; \\>=50% increase from nadir in enlargement of liver or spleen; \\>=50% increase from baseline in lymphocyte count (and to \\>=5\\*10\\^9/L) unless considered treatment-related lymphocytosis; new cytopenia (Hemoglobin b or platelets) attributable to CLL; transformation to a more aggressive histology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment Arm A (Ibrutinib + Venetoclax)"},{"description":"Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG001","title":"Treatment Arm B (Chlorambucil + Obinutuzumab)"}],"paramType":"MEDIAN","populationDescription":"Population analyzed included ITT amongst who were responders (PR or better).","reportingStatus":"POSTED","timeFrame":"Up to 2 years 10 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}